Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats
- Authors:
- Published online on: November 1, 2013 https://doi.org/10.3892/ijmm.2013.1544
- Pages: 68-76
Abstract
Introduction
Non-alcoholic fatty liver disease (NAFLD) includes non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), and NASH may lead to hepatic cirrhosis or hepatocellular carcinoma (HCC) (1,2). NAFLD/NASH can be viewed as a metabolic syndrome phenotype involving the liver, and the incidence of NAFLD has increased with corresponding increases in risk factors for metabolic syndrome, such as obesity, diabetes and hypertension. Such metabolic risk factors may promote the pathological progression of NAFLD/NASH, and NAFLD advances more rapidly in patients with a greater number of metabolic risk factors (3,4).
The incidence of hypertension is significantly higher in patients with NAFLD compared with the general population (5). Furthermore, a higher incidence of NASH has been observed in patients with NAFLD who also have hypertension and these patients are likely to progress to advanced hepatic fibrosis (6), which suggests that hypertension may promote the onset or progression of hepatitis and hepatic fibrosis. However, the possible association between hypertension and the pathological progression of NAFLD has not been fully established.
Rats fed a choline-deficient L-amino acid-defined (CDAA) diet initially develop fatty liver and hepatitis, and may subsequently progress to hepatic fibrosis and HCC (7). These findings indicate that the rat fed a CDAA diet is an appropriate animal model of the pathology of NASH. The spontaneously hypertensive rat (SHR) is produced by the mating of rats with hypertension. These rats spontaneously develop hypertension at a rate of 100% between the ages of 7 to 15 weeks, even without a high-salt diet, although a high salt load further increases the blood pressure (8).
Carbon tetrachloride (CCl4)-induced hepatic fibrosis in the SHR model is more severe than that in normotensive Wistar-Kyoto (WKY) rats used as controls (9), and SHRs receiving a choline-deficient (CD) diet show severe hepatic steatosis compared with WKY rats receiving the same diet (10). SHRs and WKY rats both originate from Wistar rats, but they diverged sufficiently long ago to now be essentially separate background strains (11). This is a limitation of the comparison of effects in these 2 types of rats. In addition, several proteins differ in the livers of SHRs and WKY rats, including proteins that induce oxidative stress (11). For this reason, we investigated the effects of hypertension induced by a high-salt diet on the severity of hepatic steatosis, liver injury and hepatic fibrosis induced by a CDAA diet in the SHR model.
Materials and methods
Animals and diets
Six-week-old male SHRs were obtained from Charles River Laboratories (Kanagawa, Japan). The rats were allowed to acclimatize to the laboratory conditions for at least 7 days at a constant temperature of 24ºC with a 12-h light-dark cycle, and fed standard chow (control diet) containing 0.27% NaCl (CE-2; Kyudo, Kumamoto, Japan) and water ad libitum. All animal experiments were approved by the Institutional Animal Care and Use Committee of Kagoshima University, Kagoshima, Japan. After the acclimatization period, the rats were placed in groups that were fed 3 different diets ad libitum: standard chow with high salt (8.0% NaCl) or normal salt (0.27% NaCl) for 7 weeks, followed by a CDAA diet containing a high (8.0% NaCl) or normal salt (0.25% NaCl) level for an additional 8 or 24 weeks (high- and normal-salt groups, respectively); or standard chow with normal salt (0.27% NaCl) for 15 or 31 weeks (control groups). Diets were obtained from Dyets Inc. (Bethlehem, PA, USA) and 30 g per day was administered to equalize the total food intake.
The resected livers were weighed and used for RNA extraction, or thin slices were immersed in 10% formalin and embedded in paraffin to make 4-μm-thick sections for staining with hematoxylin and eosin (H&E), Oil red O, Azan or Sirius Red. Blood was collected by vena cava puncture following a 12-h fast and then centrifuged. The resulting serum was stored at −80ºC.
Measurement of systolic blood pressure and serum markers
Systolic blood pressure (SBP) was monitored from 7 to 31 weeks using the tail-cuff method (model MK-1030; Muromachi Co., Ltd., Tokyo, Japan). At each time point, SBP was measured for each rat and the mean was calculated. Serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels were determined using Spotchem II-liver function 2 (Arkray Inc., Kyoto, Japan). Serum triglyceride and free fatty acid levels were determined by ELISA at SRL, Inc. (Tokyo, Japan). Fasting blood glucose (FBG) and serum immunoreactive insulin (IRI) levels were determined by ELISA (Morinaga Institute of Biological Science, Kanagawa, Japan).
Assessment of hepatic steatosis and hepatic fibrosis
Hepatic steatosis was assessed using hepatic triglyceride levels and Oil red O staining. Hepatic lipids were extracted with chloroform-methanol and measured enzymatically using a commercial kit (L-type Wako TGH; Wako Pure Chemical Industries, Osaka, Japan). Oil red O staining was performed to evaluate the accumulation of fat droplets in hepatocytes in the frozen liver sections. Sirius Red or Azan-stained sections were analyzed to evaluate fibrosis in the liver. Five fields were selected randomly from each right lobe per sample, and samples from 6 to 11 rats in each group were examined. Thus, a total of 30 to 55 fields were analyzed for each group. The ratios of the Oil red O-, Azan- or Sirius Red-stained area to the total area were quantified by image analysis. A spot RT color camera (Visitron Systems Inc., Puchheim, Germany) was used to capture and analyze the fields at ×100 magnification. Image analysis was performed using Quick Grain Standard ver. 5.0.3. software (Inotech, Hiroshima, Japan).
Assessment of hepatic mRNA levels for genes associated with liver inflammation and fibrosis
The relative levels of specific mRNAs in the resected livers were assessed by real-time polymerase chain reaction (qPCR) using a One Step SYBR PrimeScript RT-PCR kit II (Takara Bio Inc., Shiga, Japan). Total RNA was extracted from the livers using isogen (Nippon Gene, Tokyo, Japan). The expression levels of target genes were calculated relative to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was used as an endogenous control gene to normalize the target gene expression levels. All procedures were performed according to manufacturer’s instructions. mRNA levels were determined for tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, heme oxygenase (HO)-1, α-smooth muscle actin (SMA), transforming growth factor (TGF)-β1 and tissue inhibitor of metalloproteinase (TIMP)-1. PCR primers were obtained from Takara Bio Inc. The primer sequences used are listed in Table I.
Statistical analysis
A statistical comparison among groups was performed using the Tukey-Kramer test. A Student’s t-test was used for a comparison between 2 groups. A value of P<0.05 was considered to indicate a statistically significant difference. Data are presented as the means ± standard deviation (SD).
Results
Systolic blood pressure is affected by salt levels, but not by the CDAA diet
SBP gradually increased until 15 weeks in the high- and normal-salt groups. The increase in SBP was significantly greater after 7 weeks on the standard diet in the high-salt group compared with the normal-salt group and this difference continued after the CDAA diet commenced. By contrast, SBP did not differ between the normal-salt groups fed a CDAA or standard diet (Fig. 1).
Metabolic parameters after 8 weeks on the CDAA diet
There were no differences in dietary intake between the high- and normal-salt groups due to dietary restrictions during the study period; however, body weight was significantly lower and the liver/body weight ratio was significantly higher in the high-salt group compared with the normal-salt and control groups after 8 weeks on the CDAA diet (both P-values <0.05). FBG levels were significantly higher in the high-salt group compared with the other 2 groups. Serum insulin levels tended to be higher in the high-salt group compared with the normal-salt group after 8 weeks; however, these levels in the CDAA groups were not significantly higher than those in the control group. Serum triglyceride levels were significantly higher in the CDAA groups compared with the control group; however, there was no difference between the high- and normal-salt groups. Serum free fatty acids were significantly higher in the normal-salt group compared with the high-salt group, and lowest in the control group (Table II).
Severity of hepatic steatosis after 8 weeks on the CDAA diet
Micro- and macrovesicular steatosis was clearly visible in the H&E-stained liver sections from the rats fed a CDAA diet with normal- and high-salt for 8 weeks (Fig. 2A). The hepatic fat area based on Oil red O staining and the hepatic triglyceride content was significantly higher in the CDAA groups compared with the control group (Fig. 2B and C). However, hepatic steatosis did not differ between the 2 salt groups fed a CDAA diet (Fig. 2B and C).
Liver injury after 8 weeks on the CDAA diet
Serum ALT levels were significantly higher in the high-salt group compared with the normal-salt group (P<0.05) (Fig. 3). Serum ALP levels were significantly higher in the high-salt group compared with the control group and showed a tendency to be higher in the high-salt group compared with the normal-salt group (Fig. 3).
Hepatic mRNA levels after 8 weeks on the CDAA diet with high or low salt
The mRNA expression levels for TNF-α and IL-6 did not differ between the 2 salt groups after 8 weeks on the CDAA diet; however, IL-6 levels were relatively higher in the high-salt group compared with the normal-salt and control groups (Fig. 4). By contrast, hepatic mRNA levels for IL-10 and HO-1 were significantly lower in the high-salt group compared with the normal-salt group (Fig. 4). However, the hepatic mRNA level for IL-10 was higher and that for HO-1 was lower in the normal-salt group compared with the control group.
Metabolic parameters after 24 weeks on the CDAA diet
Body weight was significantly lower and the liver/body weight ratio was significantly higher in the high-salt group compared with the normal-salt group after 24 weeks on the CDAA diet. FBG levels were relatively higher in the high-salt group compared with the normal-salt and control groups. Serum insulin levels tended to be higher in the high-salt group compared with the normal-salt group; however, these levels were lower than those in the control group. Serum triglyceride levels were significantly higher in the CDAA groups compared with the control group, but did not differ between the high- and normal-salt groups. The levels of serum free fatty acids were significantly higher in the normal-salt group compared with those in the control group (Table III).
Severity of hepatic fibrosis after 24 weeks on the CDAA diet with high or low salt
The CDAA diet was administered from week 7 to week 31 (a total of 24 weeks) with or without high salt for the induction of liver fibrosis (Fig. 1). Liver fibrosis assessed by Sirius Red and Azan staining was significantly more severe in the high-salt group compared with the normal-salt and control groups (Fig. 5). The hepatic mRNA levels for α-SMA were significantly higher in the high-salt group compared with the normal-salt and control groups (Fig. 6), and hepatic TGF-β1 and TIMP-1 mRNA levels tended to be higher in the high-salt group compared with the normal-salt group. By contrast, hepatic mRNA levels for IL-10 and HO-1 were significantly lower in the high-salt group compared with those in the normal-salt group, whereas the hepatic mRNA level of IL-10 was significantly higher and that of HO-1 tended to be lower in the normal-salt group compared with the control group (Fig. 6).
Discussion
The prevalence of NAFLD including NASH has increased with an increase in the incidence of metabolic syndrome, which includes obesity, diabetes, dyslipidemia and hypertension (12–16). Hypertension, high levels of ALT and insulin resistance have all been associated with NASH and liver fibrosis (6); however, the effect of hypertension on NAFLD or NASH at the molecular level is uncertain. In this study, we investigated the mechanisms through which hypertension affects the degree of hepatic steatosis, liver injury and hepatic fibrosis induced by a CDAA diet in a hypertensive rat model. The results revealed that hypertension induced by a high-salt diet had a negligible effect on the progression of hepatic steatosis in rats, but may be a potential risk factor for liver injury and hepatic fibrosis due to glucose intolerance and decreased IL-10-mediated and HO-1-induced anti-inflammatory effects.
Ikuta et al concluded that hypertension may have an effect on the progression of NASH (10) and Hsu also suggested that hypertension may induce severe hepatic fibrosis (9). However, these reports are limited due to their dependence on comparing SHRs and normotensive WKY rats, which are clearly different despite having a similar origin (11). By contrast, we adjusted blood pressure using 2 salt levels in the SHR model. In our study, SBP gradually increased over the study period and the increase in SBP was significantly more severe in the high-salt group compared with the normal-salt group. By contrast, SBP did not differ between the normal-salt group fed a CDAA diet and the controls fed a standard diet with a normal-salt level. SBP was also suppressed by an anti-hypertensive agent (data not shown). Thus, these results demonstrate that the increase in SBP in the SHR model was independent of diet, apart from the salt level, and therefore our results reveal a direct mechanistic effect of hypertension on NAFLD/NASH.
Hypertension has been shown to reduce the plasma levels of IL-10 (17) and we also found that hypertension inhibited the expression of IL-10 in the livers of CDAA-fed rats. Treatment with IL-10 in vivo has been shown to significantly reduce SPB in hypertensive mice (18). IL-10 is a potent anti-inflammatory cytokine that plays a pivotal role in the regulation of immune and inflammatory responses. The inhibition of IL-10 has been shown to promote the expression of inflammatory cytokines, reduce insulin signaling and activate gluconeogenic and lipidogenic pathways in an animal model of diet-induced fatty liver disease (19). In addition, the upregulation of HO-1 has been shown to induce a reduction in the levels of cytokines, adhesion molecules, chemokines and neutrophil accumulation, and to ameliorate organ injury in a state of shock (20–22). As previously demonstrated, the induction of HO-1 reduces hepatic ischemia reperfusion injury (23), hepatic injury after trauma hemorrhage (24) and renal oxidative stress in diabetic SHRs (25). The inhibition of HO-1 may also be associated with acetaminophen-induced liver injury (26). Thus, HO-1 is thought to play a protective role in several organs under various deleterious conditions. IL-10 also inhibits hepatitis (27,28) and this inhibition may occur through a mechanism involving increased HO-1 expression induced by an increase in IL-10 levels (29). Furthermore, in our study, in the CDAA-fed rats, the normal-salt group showed higher levels of IL-10 and lower levels of HO-1 compared with the control group. This higher level of IL-10 may be due to a feedback mechanism against hepatitis induced by CDAA, although the CDAA diet may reduce HO-1 expression. By contrast, hypertension inhibited IL-10 and HO-1 expression, with a resultant increase in ALT to a level higher than that caused by the CDAA diet alone. In addition, indirect evidence indicates that IL-10 exerts a protective effect on endothelial function in diabetes and hypertension (17,30). IL-10 has also been shown to inhibit the activation of hepatic stellate cells and decrease hepatic fibrosis and apoptosis in a CCl4-induced rat liver fibrosis model (31,28). These findings suggest that CDAA-induced hepatic fibrosis progresses more in SHRs fed a high-salt diet compared with those fed a normal-salt diet due to the inhibition of IL-10 and reduced HO-1 expression. Thus, we speculate that the normal-salt group had increased IL-10 expression to compensate for liver injury and hepatic fibrogenesis induced by the CDAA diet, but the high-salt group could not compensate in the same manner due to the inhibition of IL-10 and HO-1 by hypertension.
Hypertension is associated with NAFLD/NASH, increased diastolic blood pressure has been linked to hepatic fat content (32), and the incidence of NAFLD in patients with systolic hypertension is twice that in the general population (33). Donati et al also found that the prevalence of fatty liver in patients with hypertension without diabetes and obesity was 3-fold higher than that in patients with normal blood pressure (34). These patients have higher homeostasis model assessment-insulin resistance (HOMA-IR) scores, and hypertension may trigger insulin resistance, which may induce fatty liver. However, our study on rats showed that hypertension caused by a higher salt load did not influence the degree of fatty deposition in the liver. The CD diet model does not present with insulin resistance (10) and hyperinsulinemia was not observed in CDAA loading in the SHR model with or without high salt, compared with the control group fed a standard diet in the current study. By contrast, FBG and serum insulin levels were higher in the high-salt group compared with the normal-salt group. HOMA-IR calculated from FBG and serum insulin levels in the high-salt group was higher than that in the normal-salt group (data not shown). Therefore, hypertension may induce glucose intolerance or insulin resistance in the SHR model. Hepatic steatosis induced by a CDAA diet may generally be severe, but insulin resistance should not be critical in hepatic steatosis induced by a CDAA diet, which may mask the effect of hypertension on hepatic steatosis. Therefore, the effect of hypertension on the severity of hepatic steatosis requires further investigation using other fatty liver models.
There are well known associations between hypertension and insulin resistance (35–37). Higher insulin resistance may lead to hypertension due to a decrease in nitric oxide (NO), the facilitation of a sympathetic nerve response and an increase in vascular smooth muscle contraction, while hypertension induced by a high-salt diet can increase insulin resistance (38,39). In our study, there was a possible association between hypertension induced by a higher salt load and glucose intolerance or insulin resistance in the CDAA-fed SHR model. Insulin resistance is linked to hepatic fibrosis (40), and peroxisome proliferator-activated receptor (PPAR)-γ agonists that improve insulin resistance also improve the pathology of NAFLD/NASH (41). The finding that hypertension induced by a higher salt load contributed to the progression of hepatic fibrosis suggests that glucose intolerance or insulin resistance induced by hypertension may be factors in the acceleration of hepatic fibrosis.
The pathological progression of NAFLD/NASH is not yet fully understood (42), but the ‘two hit theory’ is widely supported as the pathogenic mechanism of NASH (43). In this theory, it is proposed that the accumulation of triglycerides in hepatic cells (first hit) and then oxidative stress, lipid peroxidation and endotoxins increase cytokine levels and insulin resistance, which then leads to liver injury and progression to hepatic fibrosis (second hit). Our results suggest that the reduced expression of IL-10 and/or HO-1 with a consequent reduction in the inhibition of anti-inflammatory effects, and increased glucose intolerance or insulin resistance, may be involved in the hypertension-mediated exacerbation of liver injury and the acceleration of hepatic fibrosis. Thus, hypertension may be a contributing factor to the second hit rather than the first hit in NASH. Furthermore, our results suggest that aggressive anti-hypertensive therapy is required in patients with NAFLD/NASH accompanied by hypertension for the prevention of cardiovascular diseases and the inhibition of the progression of hepatic diseases.
Acknowledgements
We thank Yuko Morinaga, Etsuko Horiguchi and Ayaka Hamabe for their technical assistance. This study was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (no. 23590981), and the Ministry of Health, Labour and Welfare of Japan (H20-Hepatitis-general-008) and the Takeda Science Foundation.
References
|
Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF and Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 51:1972–1978. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yasui K, Hashimoto E, Tokushige K, et al: Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res. 42:767–773. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Adams LA, Lymp JF, St Sauver J, et al: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 129:113–121. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hamaguchi M, Kojima T, Takeda N, et al: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 143:722–728. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
López-Suárez A, Guerrero JM, Elvira-González J, Beltrán-Robles M, Cañas-Hormigo F and Bascuñana-Quirell A: Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase. Eur J Gastroenterol Hepatol. 23:1011–1017. 2011. | |
|
Dixon JB, Bhathal PS and O’Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 121:91–100. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Nakae D, Yoshiji H, Mizumoto Y, et al: High incidence of hepatocellular carcinomas induced by a choline deficient L-amino acid defined diet in rats. Cancer Res. 52:5042–5045. 1992.PubMed/NCBI | |
|
Matsui H, Ando K, Kawarazaki H, et al: Salt excess causes left ventricular diastolic dysfunction in rats with metabolic disorder. Hypertension. 52:287–294. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu CT: Ultrastructural changes in liver damage induced by carbon tetrachloride in spontaneously hypertensive rats and Wistar-Kyoto rats. J Auton Nerv Syst. 70:79–83. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Ikuta T, Kanno K, Arihiro K, et al: Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: Evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis. Hepatol Res. 42:310–320. 2012. View Article : Google Scholar | |
|
Svoboda DS and Kawaja MD: Changes in hepatic protein expression in spontaneously hypertensive rats suggest early stages of non-alcoholic fatty liver disease. J Proteomics. 75:1752–1763. 2012. View Article : Google Scholar | |
|
Amarapurkar DN, Hashimoto E, Laurentius LA, et al: Howcommon is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 22:788–793. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lewis JR and Mohanty SR: Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 55:560–578. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kojima S, Watanabe N, Numata M, Ogawa T and Matsuzaki S: Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 38:954–961. 2003.PubMed/NCBI | |
|
Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D and Dina L: Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis. 17:255–260. 2008.PubMed/NCBI | |
|
Jimba S, Nakagami T, Takahashi M, et al: Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 22:1141–1145. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Matrougui K, Abd Elmageed Z, Kassan M, et al: Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. Am J Pathol. 178:434–441. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kassan M, Galan M, Partyka M, Trebak M and Matrougui K: Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol. 31:2534–2542. 2011. | |
|
Cintra DE, Pauli JR, Araújo EP, et al: Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol. 48:628–637. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Shen XD, Ke B, Zhai Y, et al: Toll-like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant. 5:1793–1800. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HP, Choudhry MA, Shimizu T, et al: Mechanism of the salutary effects of flutamide on intestinal myeloperoxidase activity following trauma-hemorrhage: up-regulation of estrogen receptor-β-dependent HO-1. J Leukoc Biol. 79:277–284. 2006.PubMed/NCBI | |
|
Liu FC, Hwang TL, Lau YT and Yu HP: Mechanism of salutary effects of astringinin on rodent hepatic injury following trauma-hemorrhage: Akt-dependent hemeoxygenase-1 signaling pathways. PLoS One. 6:e259072011. View Article : Google Scholar : PubMed/NCBI | |
|
Devey L, Mohr E, Bellamy C, et al: c-Jun terminal kinase-2 gene deleted mice overexpress hemeoxygenase-1 and are protected from hepatic ischemia reperfusion injury. Transplantation. 88:308–316. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yu HP, Yang SC, Lau YT and Hwang TL: Role of Akt-dependent up-regulation of hemeoxygenase-1 in resveratrol-mediated attenuation of hepatic injury after trauma hemorrhage. Surgery. 148:103–109. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Elmarakby AA, Faulkner J, Baban B and Sullivan JC: Induction of hemeoxygenase-1 reduces renal oxidative stress and inflammation in diabetic spontaneously hypertensive rats. Int J Hypertens. 2012:9572352012. View Article : Google Scholar : PubMed/NCBI | |
|
Hou HS, Liao CL, Sytwu HK, et al: Deficiency of interleukin-15 enhances susceptibility to acetaminophen-induced liver injury in mice. PLoS One. 7:e448802012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou YC, Chen S, Cao JJ, Chen SY, Xie YF and Niu QX: Adenovirus-mediated viral interleukin-10 gene transfer prevents concanavalin A-induced liver injury. Dig Liver Dis. 44:398–405. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang LJ, Zheng WD, Shi MN and Wang XZ: Effects of interleukin-10 on activation and apoptosis of hepatic stellate cells in fibrotic rat liver. World J Gastroenterol. 12:1918–1923. 2006.PubMed/NCBI | |
|
Lee TS and Chau LY: Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med. 8:240–246. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gunnett CA, Heistad DD and Faraci FM: Interleukin-10 protects nitric oxide-dependent relaxation during diabetes: role of superoxide. Diabetes. 51:1931–1937. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang LJ, Zheng WD, Chen YX, et al: Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology. 54:2092–2098. 2007.PubMed/NCBI | |
|
Hamaguchi M, Kojima T, Takeda N, et al: Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 13:1579–1584. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Donati G, Stagni B, Piscaglia F, et al: Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 53:1020–1023. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Pollare T, Lithell H and Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 39:167–174. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Raitakari OT, Porkka KV, Rönnemaa T, et al: The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. The cardiovascular risk in young finns study. Diabetologia. 38:1042–1050. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Allemann Y, Horber FF, Colombo M, et al: Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Lancet. 341:327–331. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Ogihara T, Asano T, Ando K, et al: High-salt diet enhances insulin signaling and induces insulin resistance in Dahl salt-sensitive rats. Hypertension. 40:83–89. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ogihara T, Asano T and Fujita T: Contribution of salt intake to insulin resistance associated with hypertension. Life Sci. 73:509–523. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Petta S, Macaluso FS, Barcellona MR, et al: Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. PLoS One. 7:e511652012. | |
|
Aithal GP, Thomas JA, Kaye PV, et al: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 135:1176–1184. 2008. View Article : Google Scholar | |
|
Cohen JC, Horton JD and Hobbs HH: Human fatty liver disease: old questions and new insights. Science. 332:1519–1523. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Day CP and James OF: Steatohepatitis: a tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. |
